Tafasitamab in DLBCL

An interview with Lymphoma Hub Chair Gilles Salles on the use of tafasitamab in patients with diffuse large B cell lymphoma (DLBCL).

BLA submitted to FDA for loncastuximab tesirine in relapsed/refractory DLBCL

On September 21, 2020, a Biologics Licence Application (BLA) was submitted to the U.S. Food and Drug Administration (FDA)...

The impact of extra copies of MYC, BCL2, and BCL6 on outcome in patients with diffuse large B-cell lymphoma

High-grade B-cell lymphoma (HGBCL) with translocations in MYC, BCL2, and/or BCL6, termed...

Phase I results suggest a tolerable safety profile for avadomide and obinutuzumab in patients with R/R B-cell NHL

Jean-Marie Michot et al. conducted a phase 1b study, CC-122-NHL-001 (NCT02417285), to...

Tucidinostat received orphan drug designation in Japan for the treatment of R/R ATL

On September 28, 2020, tucidinostat (HBI-8000) received orphan drug designation by the Japanese Ministry of Health,...

FDA grants priority review for crizotinib in pediatric ALK-positive R/R ALCL

The U.S. Food and Drug Administration (FDA) has accepted and granted priority review of a supplemental new drug application...

Tolinapant receives orphan drug designation from the FDA for the treatment of T-cell lymphoma

On August 31, 2020, the U.S. Food & Drug Administration (FDA) granted orphan drug designation to...

A retrospective study of the clinical and pathological features of peripheral T-cell lymphomas in a Spanish population

Subclassifying T-cell lymphomas (TCLs) is difficult due to the heterogeneity and...

A new prognostic model is proposed for follicular lymphoma

Early disease progression after first-line therapy is associated with poor outcomes in patients with advanced-stage follicular lymphoma (FL)....

Phase I results suggest a tolerable safety profile for avadomide and obinutuzumab in patients with R/R B-cell NHL

Jean-Marie Michot et al. conducted a phase 1b study, CC-122-NHL-001 (NCT02417285), to...

Study of tandem CD19/CD20 CAR-engineered T cells

During the American Society of Clinical Oncology (ASCO) Virtual Meeting 2020, Yajing Zhang presented the results of an open-label, single-arm, phase...

The FDA accepts a supplemental biologics license application for axicabtagene ciloleucel in patients with R/R FL or MZL

On September 4, 2020, the U.S. Food and Drug Administration (FDA) accepted a...